Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified

Modern Pathology

Volumn 29, Issue 8, 2016, Pages 854-864

  Wang, Sa A ^a   Tam, Wayne ^b   Tsai, Albert G ^c   Arber, Daniel A ^c   Hasserjian, Robert P ^d   Geyer, Julia T ^b   George, Tracy I ^e   Czuchlewski, David R ^e   Foucar, Kathryn ^e   Rogers, Heesun J ^f   Hsi, Eric D ^f   Rea, B Bryan ^g   Bagg, Adam ^g   Cin, Paola Dal ^h   Zhao, Chong ^a   Kelley, Todd W ⁱ   Verstovsek, Srdan ^a   Bueso Ramos, Carlos ^a   Orazi, Attilio ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^f LERNER RESEARCH INSTITUTE   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h BRIGHAM AND WOMEN S HOSPITAL   (United States)

ⁱ UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CBL PROTEIN; CORTICOSTEROID; CYCLOSPORIN; DASATINIB; HYDROXYUREA; IMATINIB; INTERFERON; LACTATE DEHYDROGENASE; METHOTREXATE; NOTCH1 RECEPTOR; TRANSCRIPTION FACTOR EZH2;

ADOLESCENT; ADULT; AGED; ALLELE; ANEMIA; ARTICLE; ASXL1 GENE; BLAST CELL; BONE MARROW; CANCER CHEMOTHERAPY; CELL STRUCTURE; CHRONIC DISEASE; CLINICAL FEATURE; CLONAL VARIATION; CYTOGENETICS; DISEASE CLASSIFICATION; DISEASE SPECIFIC SURVIVAL; DYSERYTHROPOIESIS; EDEMA; EOSINOPHIL COUNT; EOSINOPHILIC LEUKEMIA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE MUTATION; GENE REARRANGEMENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN TISSUE; HYPEREOSINOPHILIC SYNDROME; IDIOPATHIC DISEASE; KARYOTYPE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEGAKARYOCYTE; MORPHOLOGY; NEXT GENERATION SEQUENCING; NIGHT SWEAT; PRIORITY JOURNAL; RHEUMATIC DISEASE; SETBP1 GENE; SKIN ALLERGY; TET2 GENE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOCYTOSIS; VERY ELDERLY; WEAKNESS; WEIGHT REDUCTION; BIOPSY; BONE MARROW EXAMINATION; CLINICAL TRIAL; COMPARATIVE STUDY; DIFFERENTIAL DIAGNOSIS; DNA MUTATIONAL ANALYSIS; GENETIC MARKER; GENETIC PREDISPOSITION; GENETICS; HIGH THROUGHPUT SEQUENCING; KAPLAN MEIER METHOD; LEUKEMIA; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MUTATION; PATHOLOGY; PHENOTYPE; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOPSY; BONE MARROW EXAMINATION; DIAGNOSIS, DIFFERENTIAL; DNA MUTATIONAL ANALYSIS; FEMALE; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; HYPEREOSINOPHILIC SYNDROME; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIER ESTIMATE; KARYOTYPE; LEUKEMIA; MALE; MIDDLE AGED; MUTATION; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; UNITED STATES; YOUNG ADULT;

EID: 84968615956     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2016.75     Document Type: Article

References (42)

1. Bain BJ, Gilliland DG, Horny H-P, et al. Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, or FGFR1. In: Swerdlow SH CE, Campo E, Harris NL, et al. (eds). WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press, 2008, pp 68-73.
2. Bain BJ, Gilliland DG, Vardiman JW, et al. Chronic eosinophilic leukemia, not otherwise specified. In: Swerdlow SH, Campo E, Harris NL, et al. (eds). WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press, 2008, pp 51-53.
3. Gotlib J. World Health Organization-defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and management. Am J Hematol 2015; 90: 1077-1089.
4. Ogbogu PU, Bochner BS, Butterfield JH, et al. Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol 2009; 124: 1319-1325.e3.
5. Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013; 369: 2379-2390.
6. Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 2013; 369: 2391-2405.
7. Cazzola M, Kralovics R. From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms. Blood 2014; 123: 3714-3719.
8. Patel KP, Newberry KJ, Luthra R, et al. Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib. Blood 2015; 126: 790-797.
9. Tenedini E, Bernardis I, Artusi V, et al. Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms. Leukemia 2014; 28: 1052-1059.
10. Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 2014; 371: 2488-2498.
11. Genovese G, Kahler AK, Handsaker RE, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med 2014; 371: 2477-2487.
12. Xie M, Lu C, Wang J, et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med 2014; 20: 1472-1478.
13. Valent P, Klion AD, Horny HP, et al. Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol 2012; 130: 607-612.e9.
14. Thiele J, Kvasnicka HM, Facchetti F, et al. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 2005; 90: 1128-1132.
15. Yamamoto A, Kojima T, Aoki T, et al. Eosinophil hypersegmentation is a possible marker to monitor the disease activity of atopic dermatitis. Allergology International 2001; 50: 325-330.
16. Xu X. Nuclear hypersegmentation of neutrophils, eosinophils, and basophils due to hydroxycarbamide (hydroxyurea). Blood 2014; 124: 1392.
17. Shen W, Szankasi P, Sederberg M, et al. Concurrent detection of targeted copy number variants and mutations using a myeloid malignancy next generation sequencing panel allows comprehensive genetic analysis using a single testing strategy. Br J Haematol 2016; 173: 49-58.
18. Iurlo A, Gianelli U, Beghini A, et al. Identification of kit (M541L) somatic mutation in chronic eosinophilic leukemia, not otherwise specified and its implication in low-dose imatinib response. Oncotarget 2014; 5: 4665-4670.
19. Schwaab J, Umbach R, Metzgeroth G, et al. KIT D816V and JAK2 V617F mutations are seen recurrently in hypereosinophilia of unknown significance. Am J Hematol 2015; 90: 774-777.
20. Cancer Genome Atlas Research N. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013; 368: 2059-2074.
21. Larsson CA, Cote G, Quintas-Cardama A. The changing mutational landscape of acute myeloid leukemia and myelodysplastic syndrome. Mol Cancer Res 2013; 11: 815-827.
22. Cui Y, Li B, Gale RP, et al. CSF3R, SETBP1 and CALR mutations in chronic neutrophilic leukemia. J. Hematol Oncol 2014; 7: 77.
23. Piazza R, Valletta S, Winkelmann N, et al. Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet 2013; 45: 18-24.
24. Pardanani A, Lasho TL, Laborde RR, et al. CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia. Leukemia 2013; 27: 1870-1873.
25. Wang SA, Hasserjian RP, Fox PS, et al. Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. Blood 2014; 123: 2645-2651.
26. Andersen CL, Nielsen HM, Kristensen LS, et al. Wholeexome sequencing and genome-wide methylation analyses identify novel disease associated mutations and methylation patterns in idiopathic hypereosinophilic syndrome. Oncotarget 2015; 6: 40588-40597.
27. Helbig G, Soja A, Bartkowska-Chrobok A, et al. Chronic eosinophilic leukemia-not otherwise specified has a poor prognosis with unresponsiveness to conventional treatment and high risk of acute transformation. Am J Hematol 2012; 87: 643-645.
28. Fauci AS, Harley JB, Roberts WC, et al. NIH conference. The idiopathic hypereosinophilic syndrome. Clinical, pathophysiologic, and therapeutic considerations. Ann Intern Med 1982; 97: 78-92.
29. Malcovati L, Cazzola M. The shadowlands of MDS: idiopathic cytopenias of undetermined significance (ICUS) and clonal hematopoiesis of indeterminate potential (CHIP). Hematology Am Soc Hematol Educ Program 2015; 2015: 299-307.
30. Yoshizato T, Dumitriu B, Hosokawa K, et al. Somatic mutations and clonal hematopoiesis in aplastic anemia. N Engl J Med 2015; 373: 35-47.
31. Kwok B, Hall JM, Witte JS, et al. MDS-Associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance. Blood 2015; 126: 2355-2361.
32. Cargo CA, Rowbotham N, Evans PA, et al. Targeted sequencing identifies patients with preclinical MDS at high risk of disease progression. Blood 2015; 126: 2362-2365.
33. Steensma DP, Bejar R, Jaiswal S, et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood 2015; 126: 9-16.
34. Yin CC, Peng J, Li Y, et al. Clinical significance of newly emerged isolated del(20q) in patients following cytotoxic therapies. Mod Pathol 2015; 28: 1014-1022.
35. Goswami RS, Liang CS, Bueso-Ramos CE, et al. Isolated +15 in bone marrow: disease-Associated or a benign finding?. Leuk Res 2015; 39: 72-76.
36. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114: 937-951.
37. Chusid MJ, Dale DC, West BC, et al. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore) 1975; 54: 1-27.
38. Flaum MA, Schooley RT, Fauci AS, et al. A clinicopathologic correlation of the idiopathic hypereosinophilic syndrome. I. Hematologic manifestations. Blood 1981; 58: 1012-1020.
39. Kueck BD, Smith RE, Parkin J, et al. Eosinophilic leukemia: a myeloproliferative disorder distinct from the hypereosinophilic syndrome. Hematol Pathol 1991; 5: 195-205.
40. Weller PF, Bubley GJ. The idiopathic hypereosinophilic syndrome. Blood 1994; 83: 2759-2779.
41. Weide R, Rieder H, Mehraein Y, et al. Chronic eosinophilic leukaemia (CEL): a distinct myeloproliferative disease. Br J Haematol 1997; 96: 117-123.
42. Kuk JS, Maceachern JA, Soamboonsrup P, et al. Chronic eosinophilic leukemia presenting with autoimmune hemolytic anemia and erythrophagocytosis by eosinophils. Am J Hematol 2006; 81: 458-461.